These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18268287)

  • 1. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
    Ulaner GA; Colletti PM; Conti PS
    Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
    Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.
    Lopci E; Santi I; Tani M; Maffione AM; Montini G; Castellucci P; Stefoni V; Rubello D; Fonti C; Zinzani P; Fanti S
    Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):436-41. PubMed ID: 20823812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma.
    Grgic A; Nestle U; Scheidhauer K; Puskas C; Ballek E; Hohloch K; Schubert J; König J; Pinkert J; Truemper L; Hellwig D; Kirsch CM
    Nuklearmedizin; 2011; 50(1):39-47. PubMed ID: 21057722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
    Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
    Witzig TE; Tomblyn MB; Misleh JG; Kio EA; Sharkey RM; Wegener WA; Goldenberg DM
    Haematologica; 2014 Nov; 99(11):1738-45. PubMed ID: 25150258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
    J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
    J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
    Lopci E; Santi I; Derenzini E; Fonti C; Savelli G; Bertagna F; Bellò M; Botto B; Huglo D; Morschhauser F; Zinzani P; Fanti S
    Ann Oncol; 2010 Sep; 21(9):1877-1883. PubMed ID: 20147744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early evaluation of tumor response to
    Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
    Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.